Ideaforge's revenue is likely to grow at a steady rate over the medium term, in line with geographical diversification, healthy demand, strong order book, and product addition, believes Crisil Ratings
The average trading volumes at the IFCI counter jumped over six-fold, with a combined 319.56 million equity shares changing hands on the NSE and BSE till 03:13 PM on Wednesday.
The capex execution, along with an expected industry tariff rationalisation over the next 12-24 months and improving network quality, are expected to support ARPU improvement and growth, believes ICRA
In the past four trading days, the stock price of Ashok Leyland slipped 13% after the company reported muted sales volumes with a decline of 4% YoY at 14,923 units in the month of May 2026.
Volatility in cigarette volumes and EBIT to moderate from the initial transitionary phase; and given the MRP revisions are still underway, the outlook for cigarette biz remains uncertain, analysts.
Thus far in the calendar year 2026, Apar Industries has outperformed the market by surging 67 per cent, as compared to 13.4 per cent fall in the BSE Sensex.
Backed by a resilient business plan and growing specialty chemicals portfolio and emerging export opportunities, Balaji Amines remains well placed for gradual ramping up of operations over the period.
In the past 10 trading days, Thangamayil Jewellery and Sky Gold and Diamonds soared 29 per cent and 28 per cent, respectively.
The management said the company continues to maintain a robust order book of ₹1,940 crore, providing strong revenue visibility and a healthy project pipeline across key segments.
ACME Solar launched a QIP, with reports indicating a fundraise of up to ₹2,500 crore to support growth capex, renewable energy project expansion and balance sheet strengthening.
PTC Industries rallied 5 per cent to ₹19,392 on the BSE in Tuesday's intra-day, and quoted close to its 52-week high of ₹19,439.95 touched on December 30, 2025.
In the past one month, the FMCG index has underperformed the market, by falling 5 per cent, as against 2.3 per cent decline in Nifty 50.
Indo Count Q4 results: EBITDA and margins witnessed recovery driven by higher contribution from new businesses due to absorption of incubation costs and favourable exchange rate.
Natco Pharma's management expects better FY28 with traction coming from Canada, Brazil and India besides some niche launches in the US which can translate into 15- 25 per cent PAT growth.
On the margin front, RateGain's management expects the company to deliver an EBITDA of ₹650 crore to ₹700 crore at a margin of 21.5 per cent to 22.5 per cent for FY27.
Wockhardt recently received USFDA approval for Zaynich (cefepime and zidebactam), a novel intravenous antibiotic for treating complicated urinary tract infections, including pyelonephritis, in adults.
Kemex said the company continues to remain strongly focused on its core KAVACH business, where a substantial and long-term opportunity pipeline from Indian Railways continues to evolve.
While the taxation environment for the tobacco sector presents near-term challenges, ITC aims to maintain its market standing through an integrated seed-to-smoke value chain and premium offerings.
Looking ahead, L&T's management expects sustained demand across infra, hydrocarbon, renewables, power T&D, power capabilities and water treatment in both domestic and international markets.
As volumes recover, the company expects the Auto business to move towards Adjusted Operating EBITDA and free cash flow positivity through FY27, believes Ola Electric.